These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25354180)

  • 21. Hot topics in cellular cardiac electrophysiology with potential impact on future drug design.
    Nánási PP; Kecskeméti V
    Curr Med Chem; 2011; 18(24):3595-6. PubMed ID: 21774766
    [No Abstract]   [Full Text] [Related]  

  • 22. [Beta-adrenergic receptor blockers in clinical practice].
    Czuriga I; Edes I
    Orv Hetil; 2004 Sep; 145(38):1951-60. PubMed ID: 15535106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arrhythmias and antiarrhythmic drugs: mechanism of action and structure-activity relationships II.
    Morgan PH; Mathison IW
    J Pharm Sci; 1976 May; 65(5):635-48. PubMed ID: 6770
    [No Abstract]   [Full Text] [Related]  

  • 24. [Is There Still a Need for Medical Antiarrhythmic Therapy?].
    Fischer TH
    Dtsch Med Wochenschr; 2020 Apr; 145(8):526-535. PubMed ID: 32294778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct beta-adrenergic receptor subtype signaling in the heart and their pathophysiological relevance.
    Zheng M; Han QD; Xiao RP
    Sheng Li Xue Bao; 2004 Feb; 56(1):1-15. PubMed ID: 14985822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic implications of beta-adrenergic receptor pharmacodynamic properties.
    Taira CA; Carranza A; Mayer M; Di Verniero C; Opezzo JA; Höcht C
    Curr Clin Pharmacol; 2008 Sep; 3(3):174-84. PubMed ID: 18781904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detrimental effects of beta-adrenergic stimulation on beta-adrenoceptors and microtubules in the heart.
    Hori M; Koretsune Y; Sato H; Kagiya T; Kitabatake A; Kamada T
    Heart Vessels Suppl; 1991; 6():11-7. PubMed ID: 1687922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anti-arrhythmic therapy and cardiac failure].
    Cosnay P; Babuty D; Charniot JC; Fauchier L; Fauchier JP
    Arch Mal Coeur Vaiss; 1995 Dec; 88 Spec No 5():35-41. PubMed ID: 8729298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiarrhythmic actions of two new beta adrenergic blocking agents, Kö 1313 and Kö 1366.
    Baum T; Rowles G; Shropshire AT
    J Pharmacol Exp Ther; 1971 Feb; 176(2):350-60. PubMed ID: 4105546
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical pharmacology of antiarrhythmic drugs.
    Capucci A; Aschieri D; Villani GQ
    Drugs Aging; 1998 Jul; 13(1):51-70. PubMed ID: 9679209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving concepts concerning cardiac β-adrenoceptor function in heart failure.
    James B; Desmond F
    Curr Pharm Des; 2010; 16(37):4148-58. PubMed ID: 21247393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Importance of beta 2-adrenergic receptors in heart failure].
    Brodde OE; Daul A; Michel MC; Zerkowski HR
    Z Kardiol; 1992; 81 Suppl 4():71-8. PubMed ID: 1363262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on antiarrhythmic drugs in emergency medicine.
    Stapczynski JS
    Emerg Med Clin North Am; 1988 May; 6(2):289-315. PubMed ID: 2894981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of antiarrhythmic drug effects by beta-adrenergic sympathetic stimulation.
    Sager PT
    Am J Cardiol; 1998 Aug; 82(4A):20I-30I. PubMed ID: 9737651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug treatment of chronic ventricular arrhythmia].
    Motté G; Slama M; Dinanian S; Sebag C
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():85-9. PubMed ID: 1284883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias.
    Mert KU; Mert GÖ; Morrad B; Tahmazov S; Mutlu F; Çavuşoglu Y
    Kardiol Pol; 2017; 75(8):786-793. PubMed ID: 28541596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarrhythmic agents. I. Mechanisms of action and clinical pharmacology.
    Mason DT; DeMaria AN; Amsterdam EA; Zelis R; Massumi RA
    Drugs; 1973; 5(4):261-91. PubMed ID: 4146767
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.